Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.
Marina Kremyanskaya, MD
Advertisement
Articles by Marina Kremyanskaya, MD
Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.
Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.
Advertisement
Latest Updated Articles
Dr. Kremyanskaya on Effect of CPI-0610 in Patients With MyelofibrosisPublished: January 29th 2020 | Updated:
Dr. Kremyanskaya on Responses With CPI-0610 in Patients With MyelofibrosisPublished: February 21st 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5